Skip to main
DYN
DYN logo

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 26 analyst ratings
Buy
Strong Buy 42%
Buy 42%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics Inc. has shown promising clinical results for its pipeline candidates, particularly with DYNE-251, which achieved approximately a 7% increase in normal dystrophin levels and demonstrated favorable safety alongside multiple functional improvements in Phase I trials. DYNE-101 has also displayed meaningful enhancements in disease pharmacology, evidenced by significant advances in biomarkers and patient-reported outcomes related to CNS symptoms, as well as sustained functional gains in various tests, suggesting its progress towards potential accelerated approval. Overall, the combination of compelling efficacy data and acceptable safety profiles for both DYNE-251 and DYNE-101 positions Dyne Therapeutics favorably for future clinical advancements and potential market success.

Bears say

Dyne Therapeutics Inc faces a negative outlook due to concerns regarding the efficacy and safety profile of its clinical candidates, particularly as the 6-month data for the CASI-22 cohort indicated a significant drop in splicing improvement from 25% at 3 months to 3% at 6 months. Additionally, potential payer headwinds related to reimbursement for DYNE-251 following competitive treatments may further depress the company's stock price. The inherent clinical development and regulatory risks, particularly if unexpected safety findings arise, could substantially hinder the commercial uptake of Dyne's therapeutics, adversely impacting financial performance.

Dyne Therapeutics (DYN) has been analyzed by 26 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 42% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 26 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.